

Tuesday 30th June

Antibody Distribution, Dosing and Imaging

Chairperson: Dr. Ezio Bonvini.

- 8.00 Antibody Pharmacokinetics, Dosing and Target Saturation.
Dr. Wim Bleeker, Director Translational research and Pharmacology, Genmab, The Netherlands.
- 8.20 Imaging of Engineered Antibodies.
Professor Anna Wu, UCLA, The Netherlands.
- 8.40 Pet Imaging of antibody distribution in tumours.
Professor Guus van Dongen, VUMC, The Netherlands.
- 9.00 MRS for tumour diagnosis and as a biomarker of response to therapy.
Professor John Griffiths, Cancer Research, Cambridge, UK.
- 9.20 Future developments in cancer imaging.
Dr. Leonard Fas, GE Healthcare, UK.

Clinical Experience with biologics based therapeutic antibody

Chairperson: Professor Hilde Revets.

- 9.40 Anti cancer Aptamer AS1411 in phase 11 trial for AML and RCC.
Dr. Fiona McLaughlin, VP Translational Research, Antisoma Research Ltd, UK.
- 10.00 Clinical Program for ofatumumab.
Dr. Paul Parren, Senior VP, Research and Preclinical development. Genmab, The Netherlands.
- 10.20 BITE Antibodies in clinical trials –POC and a novel platform.
Dr. Tobias Raum, Senior Director, Lead Discovery, Micromet, Germany.
- 10.40 Refreshments.
- 11.00 Cross-trial analysis of immunological and clinical data resulting from Phase1 and 11 trials of MVA-5T4 (Trovax (R)) in colorectal, renal and prostate cancer patients.
Dr. Richard Harrop, VP Clinical immunology, Oxford Biomedica, UK.
- 11.20 PSA-TRICOM Immunotherapy for prostate cancer survival data and a new paradigm.
Dr. James Gulley, Director Clinical Trials Group. NIH, USA.

Future advances in novel biologics platform

Chairperson: Dr. Fiona McLaughlin.

- 11.50 Magnetic Nanoparticle –Application in healthcare.
Professor Quentin Pankhurst, Director, Davy-Faraday, Laboratories, Royal Institutions, UK.
- 12.10 Engineering T Cells.
Professor Robert Hawkins, Director Medical Oncology, Cancer Research, Manchester, UK.
- 12.30 Delivering on a Promise-Synthetic vectors for cancer gene therapy.
Dr. Andreas Schatzlein, Reader, Pharmaceutical and Biological Chemistry, School of Pharmacy, London, UK.
- 1.00 Lunch
- 2.00 Magnetic tumour targeting for gene therapy.
Professor Jon Dobson, Institute for science and technology in medicine Keele University, UK.
- 2.20 Clinical application of stem cells.
Professor Nagy A. Habib, Imperial College, London, UK
- 2.40 Mammary stem and progenitor cells understanding the cellular context of breast tumours.
Professor John Stingl, Cancer Research, Cambridge, UK.
- 3.00 Estrogen receptor expression in stem progenitor cells defines a hierarchy of cellular differentiation in normal and malignant breast epithelium.
Dr. Gabriela Dontu, Kings' College, Guy's Hospital, London, UK.
- 3.20 Concludes

Contact



Dr. G. Subramanian
44 Oaken Grove, Maidenhead,
Berkshire, SL6 6HH, UK
Tel: +44 (0) 7960 139108
Fax: +44 (0) 1628 671448
Email: gsub@subramanian.org.uk
Web: www.subramanian.org.uk

WORLD BIOPHARM FORUM 2009

CANCER BIOLOGICS AND THERAPY



29 – 30 June 2009
ROBINSON COLLEGE
CAMBRIDGE, UK

Produced by Hayward Design & Print • 01227 721864 • www.hayward-design.co.uk

Please complete the registration form in **BLOCK LETTERS** and post it with your full payment to Dr. G. Subramanian, 44 Oaken Grove, Maidenhead, Berkshire, SL6 6HH, UK or email to gsub@subramanian.org.uk to reserve your place which will be confirmed upon the receipt of your payment in full.

Title (Prof. Dr. Mr. Mrs. Ms.):

Full Name:

Job Title:

Organisation:

Address:

.....

..... Postcode:

Country:

Tel:

Fax:

Email:

Any Special Dietary Requirement:

Registration fees:

Full conference package, including accommodation, all meals and gala dinner: **£610**

Early bird price (book before 24th April): **£579**

Full conference package, no accommodation, with lunch: **£455***

Early bird price (book before 24th April): **£429***

*non resident for attending gala dinner add £40

For students and block booking contact

gsub@subramanian.org.uk

Method of payment:

Credit Card payment online via website
www.subramanian.org.uk

Cheque payable to G. Subramanian in pound sterling only and drawn on a UK based bank

Bank Transfer

Cancellation

Should you be unable to attend, a substitute delegate is welcomed at no extra charge. A charge of 50% of the registration fee plus £100 administration charge will be made for cancellation received in writing at least a month prior to the conference.

PRIMARY SPONSOR:



1.00 Registration

1.20 Opening remarks
Dr G Subramanian.

Target Identification and Validation

Chairperson: Dr. Mike Clark.

1.30 Phenotypic screening using phage display and hybridoma technology to identify novel targets.

Dr Sandrine Guillard, Medimmune, Cambridge, UK.

1.50 Using Antibody fragments and peptide aptamers to understand cancer targets.

Dr Terence Rabbitts, FRS, Director, Leeds Institute of Molecular Medicine, Leeds, UK.

2.10 Novel aspects of EGF-R directed therapy.

Professor Thomas Valerius, Dr Mildred Scheel House University Hospital, Germany.

2.30 Identification and preclinical antitumour activity of human antibodies targeting growth factor and angiogenic ligands.

Dr. David Blakey, Chief Scientist Oncology, AstraZeneca, UK.

2.50 IgG4 Therapeutic Antibodies.

Dr. Jenine Schuurman, Associate Director, Strategic Research, Genmab, The Netherlands.

3.10 Generation of fully human anti-cancer antibodies with improved cross-reactivity and affinity profiles in comparison with existing murine, chimeric or human antibodies.

Dr. Sergej Kiprijanov, VP Discovery/ Research and preclinical development, Affitech AS, Norway.

3.30 DART- A Bi-functional antibody scaffold for oncology and other applications.

Dr. Syd Johnson, VP Antibody engineering, Macrogenics Inc., USA.

4.00 Refreshments

Optimisation of formats to enhance therapy

Chairperson: Dr. David Blakey.

4.20 Optimising the efficacy of therapeutic antibodies through appropriate selection of antibody Fc regions.

Dr. Mike Clark, Reader in Therapeutic and Molecular Immunology, University of Cambridge, Cambridge, UK.

4.40 Bispecific (Domain) antibody drugs for improved cancer therapy.

Dr. Michael Steward, Domantis, Cambridge, UK.

5.00 Nanobodies – From platform to production.

Professor Hilde Revets, Senior Director Technology, Ablynx nv, Belgium.

5.20 Antibody combination. Next generation antibody therapeutics for oncology.

Dr. Mikkel Pedersen, Symphogen, Denmark.

5.40 Antibody optimisation for enhanced effector function.

Dr. Ezio Bonvini, Senior VP, Research, Macrogenics Inc., USA.

6.00 Second Generation antibody formats for recruiting immunoeffector cells.

Professor Melvyn Little, CSO, Affimed Therapeutics AG, Germany.

8.00 Gala Dinner